University Hospitals Seidman Cancer Center launched S2419 BioFront, a Phase III program that integrates a gut microbiome intervention into an advanced kidney cancer treatment protocol. The study is positioned as the first Phase III trial incorporating a microbiome intervention within a cancer therapy regimen, aiming to test whether microbiome modulation can change treatment response. If the trial design bears out an efficacy signal, it would strengthen the case for microbiome-informed oncology regimens beyond earlier exploratory studies, with potential downstream impacts on patient selection and companion diagnostic development.